Novel C5 inhibitors are reshaping individualized care for generalized myasthenia gravis. Listen in to learn from Drs Muppidi, Narayanaswami, Kaminski, and Paul about persistent needs in gMG care, clinical differences among C5 inhibitors, and practical considerations for matching treatment decisions to patient goals, access, safety, and long-term adherence.
Presenters:
Srikanth Muppidi, MD
Clinical Professor
Department of Neurology and Neurological Sciences
Stanford University
Stanford, California
Pushpa Narayanaswami, MD, FAAN
Professor of Clinical Neurology
Harvard Medical School
Vice Chair, Clinical Operations
Department of Neurology
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Henry J. Kaminski, MD
Jeffrey Lieberman Professor of Neurosciences
Professor of Neurology, Pharmacology & Physiology
George Washington University
Principal Investigator, MGNet
Rare Disease Clinical Research Consortium
Washington, DC
Pritikanta Paul, MD
Assistant Professor of Neurology
University of California, San Francisco
Co-Director, MG Clinic
San Francisco, California
Link to full program:
https://bit.ly/4aXq3Ce
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
